Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma

Lung Cancer

Volumn 88, Issue 2, 2015, Pages 154-159

  Katsuya, Yuki ^a   Fujita, Yu ^b   Horinouchi, Hidehito ^a   Ohe, Yuichiro ^a   Watanabe, Shun ichi ^a   Tsuta, Koji ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Clone E1L3N; Immunohistochemistry; PD 1; PD L1; Thymic carcinoma; Thymoma

Indexed keywords

ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

A549 CELL LINE; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMUS CANCER; TISSUE MICROARRAY; WORLD HEALTH ORGANIZATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; THYMOMA; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; THYMOMA; THYMUS NEOPLASMS;

EID: 84926419179     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.03.003     Document Type: Article

References (37)

1. Engels E.A., Pfeiffer R.M. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003, 105(4):546-551.
2. Strobel P., Bauer A., Puppe B., Kraushaar T., Krein A., Toyka K., et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 2004, 22(8):1501-1509.
3. Lamarca A., Moreno V., Feliu J. Thymoma and thymic carcinoma in the target therapies era. Cancer Treat Rev 2013, 39(5):413-420.
4. Thompson R.H., Kuntz S.M., Leibovich B.C., Dong H., Lohse C.M., Webster W.S., et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006, 66(7):3381-3385.
5. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8(8):793-800.
6. Brown J.A., Dorfman D.M., Ma F.R., Sullivan E.L., Munoz O., Wood C.R., et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol (Baltimore, MD 1950) 2003, 170(3):1257-1266.
7. Padda S.K., Riess J.W., Schwartz E.J., Tian L., Kohrt H.E., Neal J.W., et al. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol 2015, 10(3):500-508.
8. Okazaki T., Chikuma S., Iwai Y., Fagarasan S., Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 2013, 14(12):1212-1218.
9. Taube J.M., Klein A., Brahmer J.R., Xu H., Pan X., Kim J.H., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014, 20(19):5064-5074.
10. Mimae T., Tsuta K., Takahashi F., Yoshida A., Kondo T., Murakami Y., et al. Steroid receptor expression in thymomas and thymic carcinomas. Cancer 2011, 117(19):4396-4405.
11. McCarty K.S., Miller L.S., Cox E.B., Konrath J., McCarty K.S. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985, 109(8):716-721.
12. Ruffini E., Detterbeck F., Van Raemdonck D., Rocco G., Thomas P., Weder W., et al. Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg 2014, 46(3):361-368.
13. Safieddine N., Liu G., Cuningham K., Ming T., Hwang D., Brade A., et al. Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma. J Thorac Oncol 2014, 9(7):1018-1022.
14. Boland J.M., Kwon E.D., Harrington S.M., Wampfler J.A., Tang H., Yang P., et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 2013, 14(2):157-163.
15. Zandberg D.P., Strome S.E. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014, 50(7):627-632.
16. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366(26):2443-2454.
17. McLaughlin J. Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). J Clin Oncol 2014, 32(5s). Abstract 8064.
18. Schultheis A.M., Scheel A.H., Ozretic L., George J., Thomas R.K., Hagemann T., et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer (Oxf, Engl 1990) 2015, 51(3):421-426.
19. Gao Q., Wang X.Y., Qiu S.J., Yamato I., Sho M., Nakajima Y., et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009, 15(3):971-979.
20. Wu C., Zhu Y., Jiang J., Zhao J., Zhang X.G., Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006, 108(1):19-24.
21. Ohigashi Y., Sho M., Yamada Y., Tsurui Y., Hamada K., Ikeda N., et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005, 11(8):2947-2953.
22. Hino R., Kabashima K., Kato Y., Yagi H., Nakamura M., Honjo T., et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010, 116(7):1757-1766.
23. Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007, 104(9):3360-3365.
24. Nomi T., Sho M., Akahori T., Hamada K., Kubo A., Kanehiro H., et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007, 13(7):2151-2157.
25. Chen Y.B., Mu C.Y., Huang J.A. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori 2012, 98(6):751-755.
26. Thompson R.H., Dong H., Kwon E.D. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007, 13(2 Pt 2):709s-715s.
27. Azuma K., Ota K., Kawahara A., Hattori S., Iwama E., Harada T., et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 2014, 25(10):1935-1940.
28. Lipson E.J., Vincent J.G., Loyo M., Kagohara L.T., Luber B.S., Wang H., et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation. Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013, 1(1):54-63.
29. Yang C.Y., Lin M.W., Chang Y.L., Wu C.T., Yang P.C. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer (Oxf, Engl 1990) 2014, 50(7):1361-1369.
30. Velcheti V., Schalper K.A., Carvajal D.E., Anagnostou V.K., Syrigos K.N., Sznol M., et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig 2014, 94(1):107-116.
31. Ishii H., Azuma K., Kawahara A., Yamada K., Imamura Y., Tokito T., et al. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol 2015, 10(3):426-430.
32. Droeser R.A., Hirt C., Viehl C.T., Frey D.M., Nebiker C., Huber X., et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer (Oxf, Engl 1990) 2013, 49(9):2233-2242.
33. Schalper K.A., Velcheti V., Carvajal D., Wimberly H., Brown J., Pusztai L., et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 2014, 20(10):2773-2782.
34. Konishi J., Yamazaki K., Azuma M., Kinoshita I., Dosaka-Akita H., Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004, 10(15):5094-5100.
35. Kefford R. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol 2014, 32(Suppl.). Abstract 3005.
36. Gandhi L. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): antitumor activity and association with tumor PD-L1 expression. AACR Annual Meeting 2014, Abstract CT105.
37. Antonia S. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with non-small cell lung cancer (NSCLC) treated with nivolumab (Anti-PD-1; BMS-936558; ONO-4538). 15th World Conference on Lung Cancer 2013, P2.11-035.